Anticonvulsant effects of transcranial direct-current stimulation (tDCS) in the rat cortical ramp model of focal epilepsy.
OBJECTIVE
Weak direct currents induce lasting alterations of cortical excitability in animals and humans, which are controlled by polarity, duration of stimulation, and current strength applied. To evaluate its anticonvulsant potential, transcranial direct current stimulation (tDCS) was tested in a modified cortical ramp-stimulation model of focal epilepsy.


METHODS
The threshold for localized seizure activity (TLS) was determined in freely moving rats by applying a single train of rising bipolar pulses through a unilateral epicranial electrode. After tDCS, TLS was determined repeatedly for 120 min at intervals of 15 min. The first group of animals received two sessions of cathodal tDCS at 100 microA, one for 30 and one for 60 min. A third session consisted of 60 min of anodal tDCS. A second group received cathodal tDCS at 200 microA for 15 and for 30 min, as well as anodal tDCS for 30 min.


RESULTS
Sixty minutes of cathodal tDCS at 100 microA resulted in a TLS increase lasting for >or=2 h. When the intensity was increased to 200 microA, a similar lasting TLS elevation occurred after a stimulation of just 30-min duration. In contrast, anodal tDCS at identical stimulation durations and current strengths had no significant effect on TLS.


CONCLUSIONS
The anticonvulsive effect induced by cathodal tDCS depends on stimulation duration and current strength and may be associated with the induction of alterations of cortical excitability that outlast the actual stimulation. The results lead to the reasonable assumption that cathodal tDCS could evolve as a therapeutic tool in drug-refractory partial epilepsy.
Liebetanz
David
D
Department of Clinical Neurophysiology, Georg-August-University, Göttingen, Germany. dliebet@gwdg.de
Klinker
Florian
F
Hering
Diana
D
Koch
Reinhard
R
Nitsche
Michael A
MA
Potschka
Heidrun
H
Löscher
Wolfgang
W
Paulus
Walter
W
Tergau
Frithjof
F
D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology* / Q000627:therapeutic use; D002540:Cerebral Cortex / Q000187:drug effects / Q000502:physiology*; D004195:Disease Models, Animal; D004351:Drug Resistance; D004558:Electric Stimulation; D004599:Electric Stimulation Therapy / Q000379:methods*; D004566:Electrodes; D004828:Epilepsies, Partial / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control*; D005625:Frontal Lobe / Q000502:physiology; D007839:Functional Laterality / Q000502:physiology; D008297:Male; D051381:Rats; D017208:Rats, Wistar
D000927:Anticonvulsants